------------------------------------------------------------
[link removed]


** Essential Reading and Resources
------------------------------------------------------------
March 7, 2022

Dear Advocate,

AVAC and our partners have been busy the first couple of months of 2022. Here is a round-up of essential reading and new and updated resources on AVAC.org ([link removed]) and PrEPWatch.org ([link removed]) !

Highlights From CROI
Our coverage of week one at CROI ([link removed]) featured updates on data related to the Dapivirine Vaginal Ring, injectable cabotegravir (CAB) as PrEP, vaccine science and cure research. And our week two summary ([link removed]) looked at symposia that explored how to reach key populations, the critical role of choice in effective HIV prevention, and the status of research on preventing sexually transmitted infections (STIs).

HIV Treatment Studies During COVID-19
A February commentary in JIAS ([link removed]) , coauthored by AVACer Maureen Luba ([link removed]) with a host of other experts on the topic, offered recommendations for the ethical continuation of treatment research among people living with HIV in the context of COVID-19: Mitigation strategies to safely conduct HIV treatment research in the context of COVID-19 ([link removed]) .

Transgender Voices: Call to action
The ([link removed]) Lancet ([link removed]) ’s February publication included a public letter from leading voices inhttps://www.avac.org/no-data-no-more the transgender community working in HIV research and public health. Titled, Research on transgender people must benefit transgender people ([link removed](21)02806-3/fulltext?utm_source=AVAC+Email+Updates&utm_campaign=9231e7d8e4-EMAIL_CAMPAIGN_2022_02_18_01_11&utm_medium=email&utm_term=0_6fd730be57-9231e7d8e4-130140441) , it called out exploitation in academic research and “called in” researchers to pursue priorities that offer direct benefit to transgender communities and to rely on resources such asNo Data No More: Manifesto to Align HIV Prevention Research with Trans and Gender Diverse Realities ([link removed]) .

Stakeholder Engagement Must Overcome Tokenism and More
The ethics review process is a critical opportunity for stakeholder engagement. AVACer Jessica Salzwedel ([link removed]) , CASPR ([link removed]) partner Cathy Slack ([link removed]) and other co-authors explore three themes that can make or break effective engagement in a new article in the Journal of Empirical Research on Human Research Ethics ([link removed]) : ”It’s Almost as if Stakeholder Engagement is the Annoying ‘Have-to-do'…”: Can Ethics Review Help Address the “3 Ts” of Tokenism, Toxicity, and Tailoring in Stakeholder Engagement? ([link removed])

South Africa Is Talking About Injectable CAB As PrEP and Getting Rollout Right
Leading South African publication on public interest health journalism, Spotlight ([link removed]) , reported on the excitement among advocates – and the need to plan now – to add injectable CAB as PrEP to the HIV prevention options currently available. Check out two new stories: Start planning HIV prevention injection rollout, experts say ([link removed]) and Prioritise HIV prevention injection, activists say ([link removed]) .

Many Angles On PrEP And Resources For Advocacy
For context on injectable CAB as PrEP, resources to support the rollout of the ring, and a look at the research and development pipeline of next generation PrEP, check out PrEP and more PrEP: An update and important resources ([link removed]) .

Research Fundamentals
What is an endpoint in clinical research and why does it matter? POZ ([link removed]) magazine’s February issue featured a transcript ([link removed]) of AVAC’s Px Pulse podcast on this question. Hear the original nine-minute podcast here. ([link removed]) And you can find the Px Pulse archive here ([link removed]) .

We hope these resources offer you the context and tools you need to use your passion and add your voice to the work ahead. Keep watching this space for more, and be sure to join us on March 16, 2022 9am ET for a special webinar ([link removed]) on the Ubuntu trial ([link removed]) , hosted by the COVID Advocates Advisory Board (CAAB) ([link removed]) and our Coalition to Accelerate and Support Prevention Research (CASPR) ([link removed]) . Led by the COVID-19 Prevention Network (CoVPN), Ubuntu is a new, landmark COVID-19 vaccine trial in sub-Saharan Africa investigating the efficacy of mRNA vaccines in people living with HIV against the omicron variant. Register here. ([link removed])

Best,
AVAC

============================================================
Forward This Issue Do you know someone who might be interested in receiving this newsletter?
** Forward > ([link removed])

Unsubscribe You're receiving this because you signed up for our newsletter. Not interested any longer?
** Unsubscribe > ([link removed])

Contact Us T: +1 212 796 6423
E: ** [email protected] (mailto:[email protected])
W: ** www.avac.org ([link removed])
** ([link removed])
** ([link removed])
** ([link removed])